These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20307554)

  • 1. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
    Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
    Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
    Eutamene H; Bradesi S; Larauche M; Theodorou V; Beaufrand C; Ohning G; Fioramonti J; Cohen M; Bryant AP; Kurtz C; Currie MG; Mayer EA; Bueno L
    Neurogastroenterol Motil; 2010 Mar; 22(3):312-e84. PubMed ID: 19706070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
    J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
    Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study on the effect of linaclotide in patients with chronic constipation.
    Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
    Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylate cyclase-C receptor activation: unexpected biology.
    Brierley SM
    Curr Opin Pharmacol; 2012 Dec; 12(6):632-40. PubMed ID: 23131468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for guanylate cyclase C in acid-stimulated duodenal mucosal bicarbonate secretion.
    Rao SP; Sellers Z; Crombie DL; Hogan DL; Mann EA; Childs D; Keely S; Sheil-Puopolo M; Giannella RA; Barrett KE; Isenberg JI; Pratha VS
    Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G95-G101. PubMed ID: 12881226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
    Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice.
    Schulz S; Lopez MJ; Kuhn M; Garbers DL
    J Clin Invest; 1997 Sep; 100(6):1590-5. PubMed ID: 9294128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutical approaches for treatment of irritable bowel syndrome].
    Siegert F; Nieber K
    Med Monatsschr Pharm; 2010 Aug; 33(8):285-92; quiz 293-4. PubMed ID: 21189648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
    Layer P; Stanghellini V
    Aliment Pharmacol Ther; 2014 Feb; 39(4):371-84. PubMed ID: 24433216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
    Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
    J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mice lacking the guanylyl cyclase C receptor are resistant to STa-induced intestinal secretion.
    Mann EA; Jump ML; Wu J; Yee E; Giannella RA
    Biochem Biophys Res Commun; 1997 Oct; 239(2):463-6. PubMed ID: 9344852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
    McCormack PL
    Drugs; 2014 Jan; 74(1):53-60. PubMed ID: 24293117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.